Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Conditions
Interventions
PEGCETACOPLAN (APL-2)
Locations
175
United States
Retinal Research Institue, LLC
Phoenix, Arizona, United States
Associated Retina Consultants, Ltd.
Phoenix, Arizona, United States
California Retina Consultants
Bakersfield, California, United States
Retinal Diagnostic Center
Campbell, California, United States
The Retina Partners
Encino, California, United States
Retina Consultants of Orange County
Fullerton, California, United States
Start Date
March 4, 2021
Primary Completion Date
September 5, 2025
Completion Date
September 5, 2025
Last Updated
October 24, 2025
NCT07441642
NCT07392255
NCT07144137
NCT06990269
NCT07424235
Lead Sponsor
Apellis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions